YD Bio Limited Ordinary Shares

YD Bio is a pre-commercial molecular-diagnostics company developing DNA-methylation-based early cancer detection assays. It's a $170 million market-capitalization microcap where the equity is priced on early-stage commercialization potential and the tape reflects the twelve-month collapse toward the range extreme.

Where the setup is:

• Trailing revenue is essentially zero and the operating margin is nominally at zero on the small revenue base — this is a pre-revenue-scale equity where the operating losses are captured entirely through the negative free-cash-flow yield.
• On July 2 the company announced expansion of the US laboratory footprint to 46 states, strengthening DNA-methylation early cancer detection operations — a real commercial-readiness milestone.
• The April 30 full-year 2025 financial results are the last complete disclosure — the company is a foreign-issuer structure with limited domestic reporting cadence, and there is no clear near-term earnings-print catalyst on the calendar.
• The insider tape is negligible: two directors (Chang Kochi and Lu Shao-Ta) received small 5,749-share awards and exercised 11,498-share options on June 30 at essentially zero prices — administrative equity settlement, not directional signals.
• Position sits at just 2% of the 52-week range with the tape 42% below the 50-day and 77% below the 200-day moving average — a genuinely broken chart where the beta of -0.13 reflects the microcap-tape dynamics rather than any broad-market covariance.

There is no scheduled earnings-print catalyst on the calendar — the next confirmation event is the H1 2026 report (undisclosed date) — until a first meaningful commercial-revenue milestone appears from the 46-state laboratory footprint, this remains a pre-revenue-scale microcap where the 2%-of-range extreme and the -82% twelve-month decline are the near-term counterweights against the commercialization narrative.